Matthew Bick

Matthew Bick

co-founder and Chief Executive Officer at Accipiter Biosciences
Seattle, Washington, United States

Matthew Bick is CEO and co-founder at Accipiter Biosciences. Previously, he served as Senior Director of Protein Sciences at Neoleukin Therapeutics and held senior scientist roles at Lyell Immunopharma and the University of Washington.

Recent coverage

Front-page news, podcasts and videos about Matthew

Accipiter Bio raises $10.5M more to speed AI-designed multi-target protein drugs, expanding clinical pipeline

Seattle biotech Accipiter Bio raised an additional $10.5 million from existing investors to accelerate development of AI-designed multi-target protein therapeutics and expand its team and clinical pipeline. The company, now 22 people strong and partnered with Pfizer and Kite/Gilead, will use the funds to advance three to four programs—focusing mainly on immunology alongside oncology—after emerging from stealth last year with $12.7 million.

Organizations

See all 10
  • Accipiter Biosciences co-founder and Chief Executive Officer 2023–present, Chief Executive Officer, CSO 2023 · current
  • Neoleukin Therapeutics Senior Director of Protein Sciences 2023, Director of Protein Sciences 2021–2023, Principal Scientist 2020–2021 · past
  • Lyell Immunopharma Senior Scientist / Project Lead 2019–2020 · past

Education

  • The Rockefeller University PhD, Biophysics · 2003–2010
  • University of Rochester BS, Microbiology · 1995–2000
  • University of North Carolina School of the Arts High School Diploma, Classical Guitar Performance, Composition · 1991–1995

Online

Questions about Matthew Bick

Who is Matthew Bick?

Matthew Bick has been co-founder and chief executive officer at Accipiter Biosciences since 2023. Matthew previously served as senior director of protein sciences at Neoleukin Therapeutics in 2023, senior scientist and project lead at Lyell Immunopharma from 2019 to 2020, and senior fellow at University of Washington from 2011 to 2018.

What has Matthew Bick been in the news for?

GeekWire reported in July 2026 that Matthew Bick’s company, Accipiter Biosciences, was accelerating AI-designed multi-target protein drugs and expanding its clinical pipeline. GeekWire reported in November 2025 that the company partnered with Pfizer and Kite Pharma to advance AI-designed multi-target protein therapies.

Which organizations is Matthew Bick associated with?

Matthew Bick is associated with 10 organizations, including Accipiter Biosciences as co-founder and chief executive officer since 2023, Neoleukin Therapeutics in protein sciences roles from 2020 to 2023, and Lyell Immunopharma as senior scientist and project lead from 2019 to 2020. Matthew also served as senior fellow at University of Washington from 2011 to 2018 and postdoctoral associate at The Rockefeller University from 2010 to 2011.

Where did Matthew Bick study?

Matthew Bick earned a PhD in Biophysics at The Rockefeller University from 2003 to 2010 and a BS in Microbiology at University of Rochester from 1995 to 2000. Matthew also earned a High School Diploma in Classical Guitar Performance, Composition at University of North Carolina School of the Arts from 1991 to 1995.

Where is Matthew Bick based?

Matthew Bick is based in Seattle, Washington, United States.

Where can I find Matthew Bick online?

Matthew Bick is on LinkedIn.